Basic & Clinical Medicine ›› 2018, Vol. 38 ›› Issue (9): 1342-1347.

Previous Articles     Next Articles

Mechanism and clinical effect of proprotein convertase subtilisin/kexin type 9 inhibitors to reduce serum LDL-C


  • Received:2017-11-27 Revised:2018-03-26 Online:2018-09-05 Published:2018-09-10
  • Supported by:
    Provincial basic research

Abstract: Low density lipoprotein cholesterol (LDL-C) has been demonstrated to be closely involved with Atherosclerotic cardiovascular disease (ASCVD). Clinical guidelines indicate that Statins serve as the first choice to lower LDL-C, there remains some patients can not be tolerable to statins, or even large doses of statins fail to achieve the optimal level of LDL-C. PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors can significantly reduce serum LDL-C level with good tolerance and safety. Recently, PCSK9 inhibitors have been approved to be used clinically by FDA.

Key words: Key words:LDL-C, PCSK9, PCSK9 inhibitor, LDLR

CLC Number: